Cowen analyst Boris Peaker attributes today's weakness in Stemline shares to a report from TheStreet that detailed the recent death of a patient in the ongoing BPDCN study. This purported death and its cause has not been confirmed by the company, noted Peaker, who adds that another drug, Ontak, has a black box warning for CLS, the condition that reportedly killed the patient in Stemline's study, yet the FDA did not pull the drug off the market. The analyst, who thinks SL-401's clinical profile to date makes it a leading CD123-targeting therapy candidate, views today's pullback as an overreaction and keeps an Outperform rating on Stemline shares.